NEW YORK (GenomeWeb) – Elucigene Diagnostics, a Manchester, UK-based molecular test provider, will seek US Food and Drug Administration clearance next year for a cystic fibrosis screening assay specific to the American population.
CEO Mark Street-Docherty said that the multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
